Lunai Bioworks Inc. (LNAI): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2021-06-30 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$537.4K

Year ended 2025-06-30

-60.0%

3-year compound annual growth

2016-06-30 R&D Expense (USD) 2025-06-30

Period ended	R&D Expense	Change YoY	Source filing
2025-06-30	$537.4K	-80.2%	2025-09-29, From 2024-07-01
2024-06-30	$2.71M	-35.0%	2025-09-29, From 2023-07-01
2023-06-30	$4.17M	-50.3%	2025-02-19, From 2022-07-01
2022-06-30	$8.37M	-46.7%	2023-10-02, From 2021-07-01
2021-06-30	$15.72M	n/c	2023-02-27, From 2020-07-01
2020-06-30	$4.69M	+87.9%	2021-09-24, From 2019-07-01
2019-06-30	$2.50M	+304.9%	2020-09-23, From 2018-07-01
2018-06-30	$617.0K	+883.0%	2019-09-30, From 2017-07-01
2017-06-30	$62.8K	-92.2%	2018-10-01, From 2016-07-01
2016-06-30	$804.2K	n/a	2017-11-20, From 2015-07-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Lunai Bioworks Inc. (LNAI)	2025-06-30	$537.4K	-80.2%
GT Biopharma, Inc. (GTBP)	2025-12-31	$3.47M	-40.1%
Xenetic Biosciences, Inc. (XBIO)	2025-12-31	$3.07M	-6.8%
Dermata Therapeutics, Inc. (DRMA)	2025-12-31	$2.93M	-64.3%
CNS Pharmaceuticals, Inc. (CNSP)	2025-12-31	$9.77M	+5.2%
GRI Bio, Inc. (GRI)	2025-12-31	$6.82M	+81.0%
Processa Pharmaceuticals, Inc. (PCSA)	2025-12-31	$7.81M	+7.4%
IGC Pharma, Inc. (IGC)	2025-03-31	$3.65M	-3.1%
Acurx Pharmaceuticals, Inc. (ACXP)	2025-12-31	$1.83M	-66.1%

Compare LNAI, GTBP, XBIO, DRMA side by side · Screen every company in Pharmaceutical Preparations ↗